Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2000
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373851A1 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373348A1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000CA2373193A1 Process for preparing (1r,2s,4r) -(-)-2-[(2'- {n,n-dimethylamino} -ethoxy)] -2-[phenyl] -1,7,7-tri- [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid additionsalts thereof
11/16/2000CA2373173A1 Aromatic amides
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373068A1 Spray drying of thrombin inhibitors
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372738A1 Low-dose il-1.beta.-induced photoreceptor cell rescue without retinal dysplasia
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2372496A1 Aryl amidines, compositions containing such compounds and methods of use
11/16/2000CA2372492A1 Cyclic amidines useful as nmda nr2b antagonists
11/16/2000CA2371902A1 Novel nucleic acids and proteins with interferon-beta activity
11/16/2000CA2371472A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000CA2371279A1 Recombinant vaccine against botulinum neurotoxin
11/16/2000CA2371219A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/15/2000EP1052259A1 Novel optically active aminopentane derivative
11/15/2000EP1052255A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics.
11/15/2000EP1052245A2 High purity (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them
11/15/2000EP1052243A2 Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof
11/15/2000EP1051995A2 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051994A2 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine
11/15/2000EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051980A2 Dopamine transporter imaging agents
11/15/2000EP1051975A1 Dry mix formulation for bisphosphonic acids
11/15/2000EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders
11/15/2000EP1051971A1 Patch and method for transdermal delivery of bupropion base
11/15/2000EP1051521A2 Method of screening therapeutic agents
11/15/2000EP1051429A1 Ldl related protein and uses thereof
11/15/2000EP1051416A1 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
11/15/2000EP1051415A1 Benzamide derivatives as vasopressin antagonists
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051393A1 New derivatives of sulfonic, phosphonic and phosphinic aminoalkane acids, their production and their use as medicaments
11/15/2000EP1051392A1 Adamantanecarboximidamide derivatives and their use as nmda antagonists
11/15/2000EP1051195A1 Identification of agents that protect against inflammatory injury to neurons
11/15/2000EP1051182A1 Methods of decreasing or preventing pain using spicamycin or derivatives thereof
11/15/2000EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/15/2000EP1051173A1 Derivatives of 1,3,4-oxadiazolone
11/15/2000EP1051170A1 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
11/15/2000EP1051167A1 Pharmaceutical uses of optically pure (-) -bupropion
11/15/2000EP1051166A1 Pharmaceutical uses of optically pure (+) -bupropion
11/15/2000EP1051165A2 Mitochondria protecting agents for treating mitochondria associated diseases
11/15/2000EP1051164A1 Pharmacological uses of pure (+) -bupropion
11/15/2000EP1051163A2 Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
11/15/2000EP1051161A1 Method for treating alzheimer's disease
11/15/2000EP0717635B1 Methods for regulating gastrointestinal motility
11/15/2000CN1273581A Method and reagents for N-alkylating ureides
11/15/2000CN1273579A Anthranilic acid analogs
11/15/2000CN1273534A Method for treating neurological deficits
11/15/2000CN1058495C Polycyclic systems compound and derivatives thereof as neurotransmitter release enhancers useful in the treatment of cognitive disordes and medicine containing them and its use
11/14/2000US6147230 Amino acid dysiherbaine
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147223 Lactacystin analogs
11/14/2000US6147190 Protein associated with activating cell propagation; for the treatment of a nervous system disorders; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147122 Oil in water emulsion used for injection with antimicrobial growth agent; prevents growth of escherchia, candida, pseudomonas, and staphylococcus
11/14/2000US6147110 Heterocyclic compounds
11/14/2000US6147102 Topical aqueous gel suitable for relieving sympathetically maintained peripheral neuropathic pain syndrome
11/14/2000US6147096 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
11/14/2000US6147087 Use of 1,2-Bridged 1,4-dihydropyridines as medicaments
11/14/2000US6147085 Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6147079 N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate
11/14/2000US6147075 Analgesics; psychological disorders
11/14/2000US6147073 Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors
11/14/2000US6147072 Administering antidepressant and serotonin reuptake inhibitor
11/14/2000US6147066 Use of antimineralocorticoid compounds against drug withdrawal syndrome
11/14/2000US6147063 Therapeutic substituted guanidines
11/14/2000US6147061 Antiarthritic agents; anticancer agents; oral diseases
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
11/14/2000US6146835 Nucleotide sequence; for drug screening of novel analgesics; for recombinant production of receptor
11/14/2000US6146636 Substance P antagonists comprising rosaceae plant extracts
11/14/2000US6146624 Human ubiquitin-conjugating enzymes
11/14/2000CA2308826A1 Combination therapy for the treatment of migraine
11/14/2000CA2308824A1 Combination therapy for the treatment of migraine
11/14/2000CA2308323A1 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
11/14/2000CA2188933C Apolipoprotein e polymorphism and treatment of alzheimer's disease
11/14/2000CA2105912C Nadh and nadph as drugs for treating alzheimer's disease
11/14/2000CA2080221C An improved process for the preparation of substituted indolone derivatives
11/14/2000CA2050284C Pcp receptor ligands and the use thereof
11/14/2000CA1341139C Tetrahydropyridine oxime cholinergic agents and method of treatment
11/12/2000CA2721484A1 Dopamine transporter imaging agents
11/10/2000CA2307958A1 Patch and method for transdermal delivery of bupropion base
11/09/2000WO2000067029A1 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12
11/09/2000WO2000067016A1 Methods for the identification of compounds for the treatment of alzheimer's disease
11/09/2000WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
11/09/2000WO2000066736A1 Growth factor homolog zvegf4
11/09/2000WO2000066735A2 Human ion channel proteins
11/09/2000WO2000066732A2 Laminin 8 and methods for its use
11/09/2000WO2000066730A2 Laminin 2 and methods for its use
11/09/2000WO2000066713A2 Materials and methods relating to neuronal development
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066617A1 Methods for the treatment of neuronal atrophy-associated dementia
11/09/2000WO2000066614A1 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
11/09/2000WO2000066611A1 Steroid derivatives
11/09/2000WO2000066587A2 Polyamines and their use in therapy